As 2024 draws to a close we’re taking the time to reflect on the previous twelve months at Cellomatics, the latest updates and the recognition we have received. Our CEO and Founder Dr Shailendra Singh also discusses what he believes 2025 will bring for the company.
New starters and promotions
Cellomatics began the year with an influx of eight new starters and four promotions, a reflection of the company’s expanding client base and new phase of its growth journey.
The four internal promotions include Pharmacology graduate, Oscar Neil, who joined Cellomatics as a Laboratory Assistant in August last year and was rewarded for his efforts with a promotion to Associate Scientist. Katie Hudson transitioned from Immuno-Oncology Scientist to Senior Bioassay Scientist and Alex Timmis was promoted from Senior Bioassay Scientist to Bioassay Study Manager. Dr Lara De Tomasi was also promoted to Bioassay Study and Operations Manager from Senior Bioassay Scientist.
The new starters included Senior Bioassay Scientists Daniele Baiz and Tsemay Tse, alongside Bioassay Scientists Arun Flynn, Silvana Tivadar and Klaudia Rzepecka. The team was also joined by Thomas Cox and Huan Thompson as Associate Scientists and Mariam Al-Naseri as Laboratory Administrator.
Read more about our promotions and new starters from earlier this year here.
Business development support
This summer saw Cellomatics continuing to expand its global client base by adding two new members of staff to support its business development efforts. Dr Pier Giorgio Amendola joined as Business Development Consultant for Europe and Dr Jyoti Mundra as Business Development Consultant for the US.
Of joining Cellomatics, Pier says, “Cellomatics provides a dynamic, science-driven environment that allows for close collaboration with clients and the delivery of tailored, innovative solutions. Having been a client of Cellomatics in my previous role, I value its high scientific standards and am eager to promote its capabilities to new clients, accelerating their drug development pipelines.”
Jyoti adds, “I am excited to bring my extensive business and scientific experience to help expand the customer base and to provide the opportunity for US clients to benefit from Cellomatics pre-clinical expertise.”
Learn more about Pier and Jyoti here.
Recognition
This year saw Cellomatics recognised for a number of awards and achievements, starting with the inaugural One Nucleus Awards in March where the company was shortlisted in the Best Performing R&D Service Provider of the Year category.
In April Cellomatics attended the Medilink Midlands Business Awards where the company was crowned as winners of the International Trade award. The Medilink Midlands Business Awards are an annual award ceremony for life sciences companies across the Midlands and are an opportunity for the region to come together and celebrate its achievements. Cellomatics was delighted to be named winners of the award as it was a testament to the company’s continued expansion and overseas success.
Cellomatics was also named as a finalist in the OBN and Scrip awards for Most Impactful CRO of the Year and Best Contract Research Organisation. Opposition is often fierce within these two awards with many larger CROs entering and so Cellomatics was thrilled to be shortlisted for such prestigious awards.
This year Cellomatics was recognised in Insider Magazine as one of the 15 most exciting Nottingham-based companies. Of this, Shailendra Singh says, “We are thrilled to be recognised as a Nottingham-based company to watch out for as we expand our client base and continue on our growth journey. We intend to further consolidate our position as a specialist biology CRO by broadening and deepening our service offerings this year and are looking forward to the next phase in our development.”
Latest insights
The team was thrilled that an article written by Cellomatics’ Senior Bioassay Scientist Dr Gareth Edwards was featured in Drug Discovery World earlier this year discussing models of neuroinflammation. Click here to see Gareth’s insights on the Drug Discovery website.
This year we also launched our podcast series where we hear from different members of the Cellomatics team about the work they are involved in and our Science Communication blogs which give in-depth insight into scientific research taking place at Cellomatics.
Looking to the future
Shailendra reflects on the year and discusses the future of Cellomatics for 2025 saying:
“Despite the slowdown in the life sciences sector, it has been another remarkable year for us. At Cellomatics, our unique proposition has always been to provide specialised, complex cell-based models that replicate in vivo biology. This approach is valuable across all stages of drug development, particularly in the validation of key therapeutic assets. As a specialised CRO, we have therefore effectively navigated the challenges of limited biotech funding, including project delays, reduced scope, and cost-cutting measures. These factors can strain CRO cash flow and operational budgets, but our focus has allowed us to adapt and maintain stability.
“We are seeing encouraging signs from the biotech investor community and hope this will lead to the delivery of improved therapeutics to the healthcare system, along with an increased pipeline of discovery programs in 2025.
“Cellomatics will continue to innovate and adapt to meet the evolving market needs. I would like to thank our clients for their trust in our services, my team for their dedication in executing projects, our consultants for their guidance, and our suppliers and logistics partners for their support. We look forward to an exciting journey in 2025.”
Wishing you all a relaxing festive season and a rewarding 2024!
